{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:46:40Z","timestamp":1772524000946,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1184344"],"award-info":[{"award-number":["OPP1184344"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Schistosomiasis remains an endemic parasitic disease causing much morbidity and, in some cases, mortality. The World Health Organization (WHO) has outlined strategies and goals to combat the burden of disease caused by schistosomiasis. The first goal is morbidity control, which is defined by achieving less than 5% prevalence of heavy intensity infection in school-aged children (SAC). The second goal is elimination as a public health problem (EPHP), achieved when the prevalence of heavy intensity infection in SAC is reduced to less than 1%.<\/jats:p>\n                <jats:p>Mass drug administration (MDA) of praziquantel is the main strategy for control. However, there is limited availability of praziquantel, particularly in Africa where there is high prevalence of infection. It is therefore important to explore whether the WHO goals can be achieved using the current guidelines for treatment based on targeting SAC and, in some cases, adults.<\/jats:p>\n                <jats:p>Previous modelling work has largely focused on <jats:italic>Schistosoma mansoni<\/jats:italic>, which in advance cases can cause liver and spleen enlargement. There has been much less modelling of the transmission of <jats:italic>Schistosoma haematobium,<\/jats:italic> which in severe cases can cause kidney damage and bladder cancer. This lack of modelling has largely been driven by limited data availability and challenges in interpreting these data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this paper, using an individual-based stochastic model and age-intensity profiles of <jats:italic>S. haematobium<\/jats:italic> from two different communities, we calculate the probability of achieving the morbidity and EPHP goals within 15 years of treatment under the current WHO treatment guidelines. We find that targeting SAC only can achieve the morbidity goal for all transmission settings, regardless of the burden of infection in adults. The EPHP goal can be achieved in low transmission settings, but in some moderate to high settings community-wide treatment is needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We show that the key determinants of achieving the WHO goals are the precise form of the age-intensity of infection profile and the baseline SAC prevalence. Additionally, we find that the higher the burden of infection in adults, the higher the chances that adults need to be included in the treatment programme to achieve EPHP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13071-020-04409-3","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T03:51:27Z","timestamp":1605671487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The impact of mass drug administration on Schistosoma haematobium infection: what is required to achieve morbidity control and elimination?"],"prefix":"10.1186","volume":"13","author":[{"given":"Klodeta","family":"Kura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hardwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Truscott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet","family":"Toor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Deirdre","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"4409_CR1","unstructured":"WHO. Weekly Epidemiological Record, 13 December 2019, vol. 94, 50 (pp. 601\u2013612). https:\/\/www9.who.int\/wer\/2019\/wer9450\/en\/. Accessed 4 Jun 2020."},{"key":"4409_CR2","unstructured":"WHO. Schistosomiasis: progress report 2001\u20132011, strategic plan 2012\u20132020. Geneva: World Health Organization; 2017. https:\/\/www.who.int\/neglected_diseases\/resources\/9789241503174\/en\/. Accessed 30 Apr 2019."},{"key":"4409_CR3","unstructured":"WHO. Helminth control in school age children: a guide for managers of control programmes Geneva: World Health Organization; 2016. https:\/\/www.who.int\/neglected_diseases\/resources\/9789241548267\/en\/."},{"key":"4409_CR4","first-page":"639","volume":"58","author":"KE Mott","year":"1980","unstructured":"Mott KE, Cline BL. Advances in epidemiology survey methodology and techniques in schistosomiasis. Bull World Health Organ. 1980;58:639\u201347.","journal-title":"Bull World Health Organ."},{"key":"4409_CR5","unstructured":"World Health Organization. Schistosomiasis and soil-transmitted helminthiases: number of people treated in 2016. Wkly Epidemiol Rec. 2017."},{"key":"4409_CR6","unstructured":"WHO. Preventive chemotherapy in human helminthiasis. WHO Libr Cat Publ Data. 2006;"},{"key":"4409_CR7","unstructured":"WHO. Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-age children. Geneva: World Health Organization; 2016. https:\/\/www.who.int\/schistosomiasis\/resources\/9789241501880\/en\/. Accessed 2 Dec 2019."},{"key":"4409_CR8","unstructured":"Pediatric Praziquantel Consortium. https:\/\/www.pediatricpraziquantelconsortium.org\/. Accessed 29 May 2020."},{"issue":"221(Supplement_","key":"4409_CR9","first-page":"S525","volume":"11","author":"J Toor","year":"2019","unstructured":"Toor J, Rollinson D, Turner HC, Gouvras A, King CH, Medley GF, et al. Achieving elimination as a public health problem for Schistosoma mansoni and S haematobium: When is community-wide treatment required? J Infect Dis. 2019;11(221(Supplement_5)):S525\u201330.","journal-title":"J Infect Dis."},{"issue":"(suppl_4)","key":"4409_CR10","doi-asserted-by":"publisher","first-page":"S245","DOI":"10.1093\/cid\/ciy001","volume":"66","author":"J Toor","year":"2018","unstructured":"Toor J, Alsallaq R, Truscott JE, Turner HC, Werkman M, Gurarie D, et al. Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current world health organization guidelines? Clin Infect Dis. 2018;66((suppl_4)):S245\u201352.","journal-title":"Clin Infect Dis."},{"key":"4409_CR11","doi-asserted-by":"publisher","first-page":"e0007349","DOI":"10.1371\/journal.pntd.0007349","volume":"13","author":"K Kura","year":"2019","unstructured":"Kura K, Truscott JE, Toor J, Anderson RM. Modelling the impact of a Schistosoma mansoni vaccine and mass drug administration to achieve morbidity control and transmission elimination. PLoS Negl Trop Dis. 2019;13:e0007349.","journal-title":"PLoS Negl Trop Dis."},{"key":"4409_CR12","doi-asserted-by":"publisher","first-page":"e0006717","DOI":"10.1371\/journal.pntd.0006717","volume":"12","author":"J Toor","year":"2018","unstructured":"Toor J, Turner HC, Truscott JE, Werkman M, Phillips AE, Alsallaq R, et al. The design of schistosomiasis monitoring and evaluation programmes: the importance of collecting adult data to inform treatment strategies for Schistosoma mansoni. PLoS Negl Trop Dis. 2018;12:e0006717.","journal-title":"PLoS Negl Trop Dis."},{"key":"4409_CR13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.ijpara.2007.05.004","volume":"37","author":"G Raso","year":"2007","unstructured":"Raso G, Vounatsou P, McManus DP, N\u2019Goran EK, Utzinger J. A Bayesian approach to estimate the age-specific prevalence of Schistosoma mansoni and implications for schistosomiasis control. Int J Parasitol. 2007;37:1491\u2013500.","journal-title":"Int J Parasitol."},{"key":"4409_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/bs.apar.2016.06.003","volume":"94","author":"RM Anderson","year":"2016","unstructured":"Anderson RM, Turner HC, Farrell SH, Truscott JE. Studies of the transmission dynamics, mathematical model development and the control of schistosome parasites by mass drug administration in human communities. Adv Parasitol. 2016;94:199\u2013246.","journal-title":"Adv Parasitol."},{"key":"4409_CR15","doi-asserted-by":"publisher","first-page":"e3059","DOI":"10.1371\/journal.pntd.0003059","volume":"8","author":"KM Mitchell","year":"2014","unstructured":"Mitchell KM, Mutapi F, Mduluza T, Midzi N, Savill NJ, Woolhouse MEJ. Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium. PLoS Negl Trop Dis. 2014;8:e3059.","journal-title":"PLoS Negl Trop Dis."},{"key":"4409_CR16","unstructured":"Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press; 1991. https:\/\/global.oup.com\/academic\/product\/infectious-diseases-of-humans-9780198540403?cc=gb&lang=en&."},{"key":"4409_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-308X(08)60561-8","volume":"24","author":"RM Anderson","year":"1985","unstructured":"Anderson RM, May RM. Helminth infections of humans: mathematical models, population dynamics, and control. Adv Parasitol. 1985;24:1\u2013101.","journal-title":"Adv Parasitol."},{"key":"4409_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4269\/ajtmh.2004.70.57","volume":"70","author":"CH King","year":"2004","unstructured":"King CH, Blanton RE, Muchiri EM, Ouma JH, Kariuki HC, Mungai P, et al. Low heritable component of risk for infection intensity and infection-associated disease in urinary schistosomiasis among Wadigo village populations in Coast Province. Kenya Am J Trop Med Hyg. 2004;70:57\u201362.","journal-title":"Kenya. Am J Trop Med Hyg."},{"key":"4409_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13071-016-1681-4","volume":"9","author":"D Gurarie","year":"2016","unstructured":"Gurarie D, King CH, Yoon N, Li E. Refined stratified-worm-burden models that incorporate specific biological features of human and snail hosts provide better estimates of Schistosoma diagnosis, transmission, and control. Parasit Vectors. 2016;9:428.","journal-title":"Parasit Vectors."},{"key":"4409_CR20","first-page":"189","volume":"40","author":"L Savioli","year":"1989","unstructured":"Savioli L, Dixon H, Kisumku UM, Mott KE. Control of morbidity due to Schistosoma haematobium on Pemba Island: programme organization and management. Trop Med Parasitol. 1989;40:189\u201394.","journal-title":"Trop Med Parasitol."},{"key":"4409_CR21","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1016\/j.vaccine.2020.04.078","volume":"38","author":"K Kura","year":"2020","unstructured":"Kura K, Collyer BS, Toor J, Truscott JE, Hollingsworth TD, Keeling MJ, et al. Policy implications of the potential use of a novel vaccine to prevent infection with Schistosoma mansoni with or without mass drug administration. Vaccine. 2020;38:4379\u201386.","journal-title":"Vaccine."},{"issue":"1","key":"4409_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1186\/s13071-019-3860-6","volume":"12","author":"CL Faust","year":"2019","unstructured":"Faust CL, Crotti M, Moses A, Oguttu D, Wamboko A, Adriko M, et al. Two-year longitudinal survey reveals high genetic diversity of Schistosoma mansoni with adult worms surviving praziquantel treatment at the start of mass drug administration in Uganda. Parasit Vectors. 2019;12(1):607.","journal-title":"Parasit Vectors."},{"issue":"9","key":"4409_CR23","first-page":"1151","volume":"63","author":"T Crellen","year":"2016","unstructured":"Crellen T, Walker M, Lamberton PHL, Kabatereine NB, Tukahebwa EM, Cotton JA, et al. Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin Infect Dis. 2016;63(9):1151\u20139.","journal-title":"Clin Infect Dis."},{"key":"4409_CR24","unstructured":"Africa Continent. ESPEN. https:\/\/espen.afro.who.int\/regions\/africa-continent. Accessed 8 Jun 2020."},{"key":"4409_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0035-9203(73)90079-5","volume":"67","author":"FS McCullough","year":"1973","unstructured":"McCullough FS, Bradley DJ. Egg output stability and the epidemiology of Schistosoma haematobium. Part I. Variation and stability in Schistosoma haematobium egg counts. Trans R Soc Trop Med Hyg. 1973;67:475\u201390.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"4409_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4269\/ajtmh.1968.17.38","volume":"17","author":"AW Cheever","year":"1968","unstructured":"Cheever AW. A quantitative post-mortem study of schistosomiasis mansoni in man. Am J Trop Med Hyg. 1968;17:38\u201364.","journal-title":"Am J Trop Med Hyg."},{"key":"4409_CR27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1186\/s13071-015-1138-1","volume":"8","author":"MD French","year":"2015","unstructured":"French MD, Churcher TS, Webster JP, Fleming FM, Fenwick A, Kabatereine NB, et al. Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with schistosomiasis control initiative-assisted programmes. Parasit Vectors. 2015;8:558.","journal-title":"Parasit Vectors."},{"key":"4409_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.epidem.2017.02.003","volume":"18","author":"JE Truscott","year":"2017","unstructured":"Truscott JE, Gurarie D, Alsallaq R, Toor J, Yoon N, Farrell SH, et al. A comparison of two mathematical models of the impact of mass drug administration on the transmission and control of schistosomiasis. Epidemics. 2017;18:29\u201337.","journal-title":"Epidemics."},{"key":"4409_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4269\/ajtmh.2004.71.778","volume":"71","author":"L-AT Tchuent\u00e9","year":"2004","unstructured":"Tchuent\u00e9 L-AT, Shaw DJ, Polla L, Cioli D, Vercruysse J. Efficacy of praziquantel against Schistosoma haematobium infection in children. Am J Trop Med Hyg. 2004;71:778\u201382.","journal-title":"Am J Trop Med Hyg."},{"key":"4409_CR30","volume-title":"Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee","author":"WHO Expert Committee on the Control of Schistosomiasis","year":"2002","unstructured":"WHO Expert Committee on the Control of Schistosomiasis. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. Geneva: World Health Organization; 2002. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/42588\/WHO_TRS_912.pdf"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-020-04409-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-020-04409-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:10:42Z","timestamp":1625044242000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-020-04409-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4409"],"URL":"https:\/\/doi.org\/10.1186\/s13071-020-04409-3","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"19 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"554"}}